A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)

Active, Not Recruiting

A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR) - CA184-557

Updated: 11 December, 2019 | ClinicalTrials.gov

About This Trial
Key Eligibility Criteria

Print Friendly Summary

CONSIDERING THIS TRIAL?

Print this page and the trial guide to help you talk with your doctor.

Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Print this page CA184-557

Download Study Participant’s Guide

SELECT LANGUAGE

Trial Details

Gender(s)
0-18

Age Range
Active, Not Recruiting

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Arm A: participants 12 to under 18

Drug: Ipilimumab

Arm B: participants under 12

Drug: Ipilimumab

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trials, please visit www.BMSStudyConnect.com. Inclusion Criteria: - Less than 18 years of age at first dose of monotherapy Ipilimumab used for treatment of advanced melanoma - Histological or cytological confirmation of advanced (unresectable or metastatic) melanoma Exclusion Criteria: -Participation in a clinical trial within the past 4 weeks prior to first dose with ipilimumab or concurrently Other inclusion/exclusion criteria apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

MLTNO2000046